Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT

详细信息    查看全文

• 作者：Jennifer Heimall¹ ; Jennifer Puck² ; Rebecca Buckley³ ; Thomas A. Fleisher⁴ ; Andrew R. Gennery⁵ ; Benedicte Neven⁶ ; Mary Slatter⁵ ; Elie Haddad⁷ ; Luigi D. Notarangelo⁸ ; K. Scott Baker⁹ ; Andrew C. Dietz¹⁰ ; Christine Duncan¹¹ ; Michael A. Pulsipher¹⁰ ; ^{mpulsipher@chla.usc.edu} ; Mort J. Cowan²
• 关键词：Late effects ; Pediatric allogeneic bone marrow transplantation ; Severe combined immunodeficiency
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：23
• 期：3
• 页码：379-387
• 全文大小：323 K
• 卷排序：23

文摘

Survival after HCT for SCID is >70% and can be higher in those treated prior to the onset of infections. MRD is the best source for HSC, but MMRD, MRD, and UCB have all been successfully used to treat SCID. Autoimmunity and cGVHD are seen in a minority of patients overall, but are more commonly seen in those with poor long-term outcomes. Use of pre-HCT conditioning is controversial in SCID, and further studies are needed to determine the best agents and doses to use in young infants, with particular attention to those with radiosensitive SCID who are more susceptible than others to experience poor growth and other adverse effects with use of alkylator-based chemotherapy. B cell engraftment is associated with higher likelihood of B cell function in most forms of SCID.